Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279):: A very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes

被引：39

作者：

Madar, David J. ^{[1
]}

Kopecka, Hana ^{[1
]}

Pireh, Daisy ^{[1
]}

Yong, Hong ^{[1
]}

Pei, Zhonghua ^{[1
]}

Li, Xiaofeng ^{[1
]}

Wiedeman, Paul E. ^{[1
]}

Djuric, Stevan W. ^{[1
]}

Von Geldern, Thomas W. ^{[1
]}

Fickes, Michael G. ^{[1
]}

Bhagavatula, Lakshmi ^{[1
]}

McDermott, Todd ^{[1
]}

Wittenberger, Steven ^{[1
]}

Richards, Steven J. ^{[1
]}

Longenecker, Kenton L. ^{[1
]}

Stewart, Kent D. ^{[1
]}

机构：

[1] Abbott Labs, Metab Dis Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 21期

关键词：

D O I：

10.1021/jm060777o

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes. Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9. Further modification led to an extremely potent (Ki(DPP-IV)) 1.0 nM) and selective (Ki(DPP8) > 30 mu M; Ki(DPP9) > 30 mu M) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies.

引用

页码：6416 / 6420

页数：5

共 50 条

[1] LC-MS/MS determination of 2-(4-((2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4-pyridinecarboxylic acid (ABT-279) in dog plasma with high-throughput protein precipitation sample preparation
Kim, Joseph
Flick, Jeanette
Reimer, Michael T.
Rodila, Ramona
Wang, Perry G.
Zhang, Jun
Ji, Qin C.
EI-Shourbagy, Tawakol A.
BIOMEDICAL CHROMATOGRAPHY, 2007, 21 (11) : 1118 - 1126
[2] Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist
Palucki, BL
Park, MK
Nargund, RP
Ye, ZX
Sebhat, IK
Pollard, PG
Kalyani, RN
Tang, R
MacNeil, T
Weinberg, DH
Vongs, A
Rosenblum, CI
Doss, GA
Miller, RR
Stearns, RA
Peng, QP
Tamvakopoulos, C
McGowan, E
Martin, WJ
Metzger, JM
Shepherd, CA
Strack, AM
MacIntyre, DE
Van der Ploeg, LHT
Patchett, AA
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (01) : 171 - 175
[3] 2-[3-[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline:: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
Tsu, H
Chen, X
Chen, CT
Lee, SJ
Chang, CN
Kao, KH
Coumar, MS
Yeh, YT
Chien, CH
Wang, HS
Lin, KT
Chang, YY
Wu, SH
Chen, YS
Lu, IL
Wu, SY
Tsai, TY
Chen, WC
Hsieh, HP
Chao, YS
Jiaang, WT
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (01) : 373 - 380
[4] Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)-amino]carbonyl]1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist.
Palucki, BL
Park, MK
Nargund, RP
Ye, ZX
Sebhat, IK
Pollard, PG
Kalyani, RN
Tang, R
MacNeil, T
Weinberg, DH
Vongs, A
Rosenblum, CI
Doss, GA
Miller, RR
Stearns, RA
Peng, OP
Tamvakopoulos, C
McGowan, E
Marfin, WJ
Metzger, JM
Shepherd, CA
Strack, AM
MacIntyre, DE
Van der Ploeg, LHT
Patchett, AA
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U109 - U110
[5] Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis
Sandanayaka, Vincent
Mamat, Bjorn
Mishra, Rama K.
Winger, Jennifer
Krohn, Michael
Zhou, Li-Ming
Keyvan, Monica
Enache, Livia
Sullins, David
Onua, Emmanuel
Zhang, Jun
Halldorsdottir, Gudrun
Sigthorsdottir, Heida
Thorlaksdottir, Audur
Sigthorsson, Gudmundur
Thorsteinnsdottir, Margret
Davies, Douglas R.
Stewart, Lance J.
Zembower, David E.
Andresson, Thorkell
Kiselyov, Alex S.
Singh, Jasbir
Gurney, Mark E.
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (02) : 573 - 585
[6] Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Yoshida, Tomohiro
Akahoshi, Fumihiko
Sakashita, Hiroshi
Kitajima, Hiroshi
Nakamura, Mitsuharu
Sonda, Shuji
Takeuchi, Masahiro
Tanaka, Yoshihito
Ueda, Naoko
Sekiguchi, Sumie
Ishige, Takayuki
Shima, Kyoko
Nabeno, Mika
Abe, Yuji
Anabuki, Jun
Soejima, Aki
Yoshida, Kumiko
Takashina, Yoko
Ishii, Shinichi
Kiuchi, Satoko
Fukuda, Sayaka
Tsutsumiuchi, Reiko
Kosaka, Keigo
Murozono, Takahiro
Nakamaru, Yoshinobu
Utsumi, Hiroyuki
Masutomi, Naoya
Kishida, Hiroyuki
Miyaguchi, Ikuko
Hayashi, Yoshiharu
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (19) : 5705 - 5719
[7] Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors
Certal, Victor
Halley, Frank
Virone-Oddos, Angela
Filoche-Romme, Bruno
Carry, Jean-Christophe
Gruss-Leleu, Florence
Bertin, Luc
Guizani, Houlfa
Pilorge, Fabienne
Richepin, Patrick
Karlsson, Andreas
Charrier, Veronique
Abecassis, Pierre-Yves
Vincent, Loic
Nicolas, Jean-Paul
Lengauer, Christoph
Garcia-Echeverria, Carlos
Schio, Laurent
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (06) : 1506 - 1510
[8] Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo-[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist
Ye, ZX
Guo, LQ
Barakat, KJ
Pollard, PG
Palucki, BL
Sebhata, IK
Bakshi, RK
Tang, R
Kalyani, RN
Vongs, A
Chen, AS
Chen, HY
Rosenblum, CI
MacNeil, T
Weinberg, DH
Peng, QP
Tamvakopoulos, C
Miller, RR
Stearns, RA
Cashen, DE
Martin, WJ
Metzger, JM
Strack, AM
MacIntyre, DE
Van der Ploeg, LHT
Patchett, AA
Wyvratt, MJ
Nargund, RP
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (15) : 3501 - 3505
[9] (2S, 3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide:: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Edmondson, Scott D.
Mastracchio, Anthony
Mathvink, Robert J.
He, Jiafang
Harper, Bart
Park, You-Jung
Beconi, Maria
Di Salvo, Jerry
Eiermann, George J.
He, Huaibing
Leiting, Barbara
Leone, Joseph F.
Levorse, Dorothy A.
Lyons, Kathryn
Patel, Reshma A.
Patel, Sangita B.
Petrov, Aleksandr
Scapin, Giovanna
Shang, Jackie
Roy, Ranabir Sinha
Smith, Aaron
Wu, Joseph K.
Xu, Shiyao
Zhu, Bing
Thornberry, Nancy A.
Weber, Ann E.
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (12) : 3614 - 3627
[10] (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
Yeh, Teng-Kuang
Tsai, Ting-Yueh
Hsu, Tsu
Cheng, Jai-Hong
Chen, Xin
Song, Jen-Shin
Shy, Horng-Shing
Chiou, Mei-Chun
Chien, Chia-Hui
Tseng, Ya-Ju
Huang, Chung-Yu
Yeh, Kai-Chia
Huang, Yu-Lin
Huang, Chih-Hsiang
Huang, Yu-Wen
Wang, Min-Hsien
Tang, Hung-Kuan
Chao, Yu-Sheng
Chen, Chiung-Tong
Jiaang, Weir-Torn
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3596 - 3600

← 1 2 3 4 5 →